Alembic Pharma’s Subsidiary Receives USFDA Approval for Glycopyrrolate Tablets

Alembic Pharmaceuticals Limited (Alembic) announced its wholly owned subsidiary Orit Laboratories LLC has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Glycopyrrolate Tablets USP, 1 mg and 2 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Robinul and Robinul Forte Tablets, 1 mg and 2 mg, of Casper Pharma LLC (Casper Pharma). Glycopyrrolate Tablets are indicated for use as adjunctive therapy in the treatment of peptic ulcer. Glycopyrrolate Tablets USP, 1 mg and 2 mg have an estimated market size of USD 15 million for twelve months ending December 2017 according to IQVIA. Alembic has a cumulative total of 81 ANDA approvals (68 final approvals and 13 tentative approvals) from USFDA. – Medical Buyer Bureau